Alison Murphy - Concepedia

Author

Alison Murphy

Also Known As

A Murphy, Alison A Murphy, Alison A. Murphy, Alison Murphy, Alison A. Murphy, Lempicki, Richard A., Murphy, Alison, Rebecca Muirhead

Publications

3.9K

Citations

H-Index

Concepts

All Affiliations

National Institutes of Health University College Dublin National Institute of Allergy and Infectious Diseases University of Oxford Hertie Institute for Clinical Brain Research

About

Alison Murphy is an author at National Institutes of Health specializing in medicine, cell biology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	11	1.5K
2	Business	1	1	72
3	Engineering	1	1	72
4	Natural Sciences	1	1	23
5	Public Health	1	1	38

Alison Murphy

Publications

3.8K

Citations

H-Index

Page 1

	Year	Citations
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Eugenia Abaleke, Mustafa Abbas, Sadia Abbasi, The Lancet Long CovidAntimicrobial StewardshipAntibioticsClinical InfectionPlatform Trial	2021	555
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Obbina Abani, Ali Abbas, Fatima Abbas, The Lancet	2021	516
SD-208, a Novel Transforming Growth Factor β Receptor I Kinase Inhibitor, Inhibits Growth and Invasiveness and Enhances Immunogenicity of Murine and Human Glioma Cells<b><i>In vitro</i></b>and<b><i>In vivo</i></b> Martin Uhl, Steffen Aulwurm, Jörg Wischhusen, Cancer Research	2004	410
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Obbina Abani, Ali Abbas, Fatima Abbas, The Lancet Covid-19 PandemicAntiviral TherapyClinical TrialsPlatform TrialMedicine	2022	382
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Obbina Abani, Ali Abbas, Fatima Abbas, The Lancet	2021	289
Progressive Transforming Growth Factor β1–induced Lung Fibrosis Is Blocked by an Orally Active ALK5 Kinase Inhibitor Philippe Bonniaud, Peter J. Margetts, Martin Kolb, American Journal of Respiratory and Critical Care Medicine FibrosisInflammatory Lung DiseaseLung InflammationLung Fibrosis IsImmunology	2004	252
Genome sequencing of the extinct Eurasian wild aurochs, Bos primigenius, illuminates the phylogeography and evolution of cattle Stephen D. E. Park, David A. Magee, Paul McGettigan, Genome biology	2015	221
Inhibition of Growth and Metastasis of Mouse Mammary Carcinoma by Selective Inhibitor of Transforming Growth Factor-β Type I Receptor Kinase <i>In vivo</i> Rongrong Ge, Vaishali Rajeev, Partha Ray, Clinical Cancer Research	2006	152
Role of the TGF-β/Alk5 Signaling Pathway in Monocrotaline-induced Pulmonary Hypertension Ari Zaiman, Megan Podowski, Satya Medicherla, American Journal of Respiratory and Critical Care Medicine	2008	141
Inhibition of Transforming Growth Factor β Signaling Reduces Pancreatic Adenocarcinoma Growth and Invasiveness N. J. Gaspar, Lingyun Li, Ann M. Kapoun, Molecular Pharmacology	2007	118

Page 1